Overview
Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.
Healthcare Biopharmaceuticals Other Biopharmaceuticals Finland
Financials
Key metrics
| Market capitalisation, EUR | 9,831 m |
| EPS, EUR | 3.56 |
| P/B ratio | 7.6 |
| P/E ratio | 19.6 |
| Dividend yield | 2.47% |
Income statement (2025)
| Revenue, EUR | 1,888 m |
| Net income, EUR | 500 m |
| Profit margin | 26.50% |
What ETF is Orion Oyj in?
There are 63 ETFs which contain Orion Oyj. All of these ETFs are listed in the table below. The ETF with the largest weighting of Orion Oyj is the iShares STOXX Europe Equity Multifactor UCITS ETF EUR (Dist).
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
